KR102405199B1 - 설카딘 염 - Google Patents

설카딘 염 Download PDF

Info

Publication number
KR102405199B1
KR102405199B1 KR1020217027357A KR20217027357A KR102405199B1 KR 102405199 B1 KR102405199 B1 KR 102405199B1 KR 1020217027357 A KR1020217027357 A KR 1020217027357A KR 20217027357 A KR20217027357 A KR 20217027357A KR 102405199 B1 KR102405199 B1 KR 102405199B1
Authority
KR
South Korea
Prior art keywords
salt
sulfadine
crystalline
peaks
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217027357A
Other languages
English (en)
Korean (ko)
Other versions
KR20210130157A (ko
Inventor
수잔 제이 로마노
헤일리 앤 리스
조셉 에드워드 고든 벤슨
사라 콜린스
게리 티 엘리엇
미레일 길링스
로버트 굿나우
커티스 타이리
Original Assignee
후야 바이오사이언스 인터내셔널 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후야 바이오사이언스 인터내셔널 엘엘씨 filed Critical 후야 바이오사이언스 인터내셔널 엘엘씨
Priority to KR1020227017874A priority Critical patent/KR102697726B1/ko
Publication of KR20210130157A publication Critical patent/KR20210130157A/ko
Application granted granted Critical
Publication of KR102405199B1 publication Critical patent/KR102405199B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
KR1020217027357A 2019-01-29 2020-01-28 설카딘 염 Active KR102405199B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227017874A KR102697726B1 (ko) 2019-01-29 2020-01-28 설카딘 염

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962798467P 2019-01-29 2019-01-29
US62/798,467 2019-01-29
US202062959687P 2020-01-10 2020-01-10
US62/959,687 2020-01-10
PCT/US2020/015370 WO2020159959A1 (en) 2019-01-29 2020-01-28 Sulcardine salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017874A Division KR102697726B1 (ko) 2019-01-29 2020-01-28 설카딘 염

Publications (2)

Publication Number Publication Date
KR20210130157A KR20210130157A (ko) 2021-10-29
KR102405199B1 true KR102405199B1 (ko) 2022-06-02

Family

ID=69724142

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217027357A Active KR102405199B1 (ko) 2019-01-29 2020-01-28 설카딘 염
KR1020227017874A Active KR102697726B1 (ko) 2019-01-29 2020-01-28 설카딘 염

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227017874A Active KR102697726B1 (ko) 2019-01-29 2020-01-28 설카딘 염

Country Status (16)

Country Link
US (3) US11426382B2 (https=)
EP (1) EP3917921A1 (https=)
JP (3) JP2022518906A (https=)
KR (2) KR102405199B1 (https=)
CN (2) CN115385871A (https=)
AU (1) AU2020216925B2 (https=)
BR (1) BR112021014640A8 (https=)
CA (1) CA3128152A1 (https=)
CL (1) CL2021001968A1 (https=)
CO (1) CO2021011042A2 (https=)
IL (1) IL285184B2 (https=)
MX (2) MX2021009033A (https=)
PH (1) PH12021551818A1 (https=)
SG (1) SG11202108160YA (https=)
WO (1) WO2020159959A1 (https=)
ZA (2) ZA202105344B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364223B2 (en) 2018-12-13 2022-06-21 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
CN115385871A (zh) * 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐
CA3182015A1 (en) 2020-06-12 2021-12-16 Gary Elliott Sulcardine administration for treatment of acute atrial fibrillation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042204A1 (en) 1999-12-10 2001-06-14 Shanghai Institute Of Materia Medica Chinese Academy Of Science N-substituted benzyl or phenyl aromatic sulfamides compounds and the use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299813C (zh) 2004-12-28 2007-02-14 华南理工大学 自动撕膜落料及多样性搅拌的机构和控制装置
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
CN102665714A (zh) 2009-11-17 2012-09-12 沪亚生物国际有限责任公司 心房纤颤的治疗
EP2501380B1 (en) * 2009-11-17 2016-01-27 Huya Bioscience International LLC Slow infusion of sulcardine and its salts
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CA3254279A1 (en) 2015-06-03 2025-03-18 Triastek, Inc. PHARMACEUTICAL FORMS AND RELATED USES
CA3023278C (en) 2016-05-05 2019-04-30 Triastek, Inc. Controlled release dosage form
KR20190107712A (ko) 2017-01-26 2019-09-20 트리아스텍 인코포레이티드 특정 위장 부위에서의 제어 방출의 투여 형태
CA3054403A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
US11364223B2 (en) 2018-12-13 2022-06-21 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
CN115385871A (zh) 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042204A1 (en) 1999-12-10 2001-06-14 Shanghai Institute Of Materia Medica Chinese Academy Of Science N-substituted benzyl or phenyl aromatic sulfamides compounds and the use thereof

Also Published As

Publication number Publication date
BR112021014640A8 (pt) 2022-12-20
US20200316024A1 (en) 2020-10-08
PH12021551818A1 (en) 2022-03-28
AU2020216925B2 (en) 2022-09-15
ZA202105344B (en) 2023-01-25
KR20220079688A (ko) 2022-06-13
KR102697726B1 (ko) 2024-08-21
AU2020216925A1 (en) 2021-09-02
IL285184A (en) 2021-09-30
BR112021014640A2 (pt) 2021-09-21
US20250144072A9 (en) 2025-05-08
US11426382B2 (en) 2022-08-30
CL2021001968A1 (es) 2022-01-28
ZA202107474B (en) 2022-06-29
JP2024039020A (ja) 2024-03-21
IL285184B2 (en) 2023-12-01
IL285184B1 (en) 2023-08-01
EP3917921A1 (en) 2021-12-08
US20210038568A1 (en) 2021-02-11
US11020374B2 (en) 2021-06-01
KR20210130157A (ko) 2021-10-29
JP2022518906A (ja) 2022-03-17
US20220356319A1 (en) 2022-11-10
CO2021011042A2 (es) 2022-01-17
MX2023014776A (es) 2024-01-15
JP2025165933A (ja) 2025-11-05
CN115385871A (zh) 2022-11-25
WO2020159959A1 (en) 2020-08-06
CN112638903B (zh) 2022-08-26
CA3128152A1 (en) 2020-08-06
CN112638903A (zh) 2021-04-09
MX2021009033A (es) 2021-10-13
SG11202108160YA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
US20220356319A1 (en) Sulcardine salts
ES2562843T3 (es) Forma IV de clorhidrato de ivabradina
BR112020022738A2 (pt) formas cristalinas de um inibidor tlr7/tlr8
US8361971B2 (en) Tablet formulation of ezatiostat
ES2949414T3 (es) Formas cristalinas de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiazol-6-iloxi)-N-metilpicolinamida
HK40049638B (en) Sulcardine salts
HK40079384A (en) Sulcardine salts
HK40049638A (en) Sulcardine salts
EA043571B1 (ru) Соли сулькардина
AU2019344541B2 (en) Erbumine salt of treprostinil
BR112015008931B1 (pt) Forma cristalina de (3s,3s) 4,4-disulfanodiilbis(ácido 3-aminobutano 1-sulfônico) de absd; processo para a preparação de uma forma cristalina de absd e l-lisina; e composição farmacêutica
CN105367622B (zh) 一种阿加曲班化合物
CN107793356B (zh) 一种四氢异喹啉的盐衍生物及其晶体的制备方法和应用
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
KR20250026776A (ko) 고요산혈증 또는 통풍 치료 또는 예방을 위한 화합물의 고체 결정형
EA043230B1 (ru) Эрбуминовая соль трепростинила
NZ759132B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
NZ719970A (en) Solid forms of { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
PA0105 International application

Patent event date: 20210826

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210826

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20210826

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211227

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220425

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220526

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220530

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220530

End annual number: 3

Start annual number: 1

PG1601 Publication of registration